Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Analysts' Corner
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, January 1, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), United Therapeutics Corporation (NASDAQ: UTHR), Insys Therapeutics Inc (NASDAQ: INSY), Puma Biotechnology Inc (NYSE: PBYI), and Acorda Therapeutics Inc (NASDAQ: ACOR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Pfizer Inc. Research Report
On November 8, 2013, Pfizer Inc. (Pfizer) released top-line results from its Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who switched from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant. According to Pfizer, for patients who were switched to RAPAMUNE®, 33.7% of patients achieved the primary endpoint of a = 5 ml/min/1.73m2 renal function improvement based on glomerular filtration rate from randomization to 24 months post-transplantation and 42.3% of patients continuing to take TAC achieved the primary endpoint (p=0.239). The Company stated that the primary endpoint of the study was not achieved as there was not a statistically significant difference in renal function improvement between patients who continued receiving TAC and those who switched to RAPAMUNE®. Pfizer added that the study also evaluated the safety of RAPAMUNE® and the adverse events observed in the study were in line with the known safety profile of RAPAMUNE®. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
United Therapeutics Corporation Research Report
On October 29, 2013, United Therapeutics Corporation (United Therapeutics) released its Q3 2013 financial results. The Company posted a 24.6% YoY increase in revenues to $302.2 million. Net income for the quarter was $62.7 million or $1.17 per diluted share, as compared to $78.1 million or $1.46 per diluted share in Q3 2012. Martine Rothblatt, Ph.D., United Therapeutics' Chairman and CEO, commented, "I am extremely pleased with the results of the third quarter. Our medicines are now prescribed for more PAH patients in the United States than any other company." The Company added that it expects its full-year 2013 revenue guidance for its three commercial products (Remodulin®, Tyvaso® and Adcirca®) to exceed the upper end of its previous guidance of $1.05 billion. The Full Research Report on United Therapeutics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Insys Therapeutics Inc. Research Report
On November 12, 2013, Insys Therapeutics Inc. (Insys) reported its Q3 2013 financial results with total revenues of $29.2 million versus $4.8 million in Q3 2012. The Company posted net income of $11.6 million or $0.51 per diluted share for Q3 2013, compared to a net loss of $4.3 million or $0.46 per diluted share for Q3 2012. Michael L. Babich, President and CEO, stated, "Our strong results this quarter were driven by continued prescription growth of the Subsys franchise to alleviate breakthrough pain for cancer patients. The product, with its simple, one-step administration system, has captured over 30% share of the transmucosal immediate-release fentanyl (TIRF) market, and we aim to drive further growth through execution of our marketing strategy." The Full Research Report on Insys Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download Insys Therapeutics Inc free of charge at:
Puma Biotechnology Inc. Research Report
On November 12, 2013, Puma Biotechnology Inc. (Puma Biotechnology) released its Q3 2013 financial results. The Company reported net loss applicable to common stock of $14.3 million, or $0.50 per share for Q3 2013, compared to a net loss of $25.9 million, or $1.29 per share, in Q3 2012. Puma Biotechnology's operating expenses for the quarter were down by 44.8% YoY to $14.3 million. Alan H. Auerbach, CEO and President of Puma, commented, "During the third quarter of 2013, we continued to execute on our ongoing Phase II and Phase III trials of PB272 (neratinib). During the quarter, we also initiated a Phase II trial of PB272 for the treatment of patients with solid tumors that have a HER2 activating mutation (basket trial). We anticipate seeing the first results from our basket trial in the fourth quarter of 2013 or in the beginning of 2014." The Full Research Report on Puma Biotechnology Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Acorda Therapeutics Inc. Research Report
On October 31, 2013, Acorda Therapeutics Inc. (Acorda) released its Q3 2013 financial results with total revenues of $84.9 million, up 9.7% YoY. Q3 2013 net income for the Company stood at $7.5 million, or $0.18 per diluted share, compared to $9.6 million, or $0.24 per diluted share for Q3 2012. Ron Cohen, M.D., Acorda's President and CEO, stated, "We are pleased with the continued growth and progress of the Company. AMPYRA net sales for the third quarter were in line with our expectations and we are encouraged by fourth quarter sales to date. We also have a strong cash position of approximately $350 million. The strength of the AMPYRA franchise and our balance sheet is enabling us to invest in our pipeline of promising clinical-stage compounds, which have attained a number of important milestones in 2013." The Company added that it has narrowed its 2013 AMPYRA net revenue guidance to $295-$305 million from $285-$315 million. The Full Research Report on Acorda Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.